Are cardioprotective drugs underused after a myocardial infarction in patients who suffer from chronic kidney disease?;La pharmacopée de prévention cardiovasculaire est-elle sous-utilisée chez les patients souffrant d'insuffisance rénale chronique aprs un infarctus du myocarde ?

Nephrologie et Therapeutique

Volumn 6, Issue 3, 2010, Pages 162-170

  Cardinal, Héloïse ^a,b   Madore, Franois ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Chronic kidney disease; Myocardial infarction; Secondary prevention; Therapy; Underuse

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; CHRONIC PATIENT; CLINICAL PRACTICE; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; EMBASE; HEART INFARCTION; HEART PROTECTION; HUMAN; KIDNEY FUNCTION; MEDICAL LITERATURE; MEDLINE; PATIENT CARE; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 77955657979     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.10.003     Document Type: Short Survey

References (46)

1. A.J. Collins, S. Li, J.Z. Ma, and C. Herzog Cardiovascular disease in end-stage renal disease patients Am J Kidney Dis 38 2001 S26 29
2. A.K. Cheung, M.J. Sarnak, G. Yan, J.T. Dwyer, R.J. Heyka, and M.V. Rocco Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients Kidney Int 58 2000 353 362
3. J.L. Xue, E.T. Frazier, C.A. Herzog, and A.J. Collins Association of heart disease with diabetes and hypertension in patients with ESRD Am J Kidney Dis 45 2005 316 323
4. B.P. Oberg, E. McMenamin, F.L. Lucas, E. McMonagle, J. Morrow, and T.A. Ikizler Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease Kidney Int 65 2004 1009 1016
5. G.A. Kaysen, and J.P. Eiserich The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction J Am Soc Nephrol 15 2004 538 548
6. N.S. Anavekar, J.J. McMurray, E.J. Velazquez, S.D. Solomon, L. Kober, and J.L. Rouleau Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285 1295
7. R. McPherson, J. Frohlich, G. Fodor, J. Genest, and S. Canadian Cardiovascular Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 22 2006 913 927
8. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:S1-91.
9. H.D. White, and D.P. Chew Acute myocardial infarction Lancet 372 2008 570 584
10. D.A. Redelmeier, S.H. Tan, and G.L. Booth The treatment of unrelated disorders in patients with chronic medical diseases N Engl J Med 338 1998 1516 1520
11. J.H. Han, A. Chandra, J. Mulgund, M.T. Roe, E.D. Peterson, and L.A. Szczech Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes Am J Med 119 2006 248 254
12. G.M. Chertow, S.L. Normand, and B.J. McNeil "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency J Am Soc Nephrol 15 2004 2462 2468
13. R.H. Mehta, M.T. Roe, A.Y. Chen, B.L. Lytle, C.V. Pollack Jr., and R.G. Brindis Recent trends in the care of patients with non-ST segment elevation acute coronary syndromes: insights from the CRUSADE initiative Arch Intern Med 166 2006 2027 2034
14. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.htm.
15. R. Dumaine, J.P. Collet, M.L. Tanguy, N. Mansencal, J.L. Dubois-Rande, and P. Henry Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study) Am J Cardiol 94 2004 1543 1547
16. L. Bonello, A. De Labriolle, P. Roy, D.H. Steinberg, T. Okabe, and T.L. Pinto Slottow Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome Am J Cardiol 102 2008 535 540
17. K.J. Filipiak, and G. Opolski Renal failure in patients after acute coronary syndrome - does it change the standards? From theory to practice Przegl Lek 62 2005 35 38
18. R.K. Harada, K.A. Eagle, E.M. Kline-Rogers, J. Fang, D. Smith, and D. Mukherjee Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes Indian Heart J 58 2006 222 229
19. W.C. Winkelmayer, R. Levin, and S. Setoguchi Associations of kidney function with cardiovascular medication use after myocardial infarction Clin J Am Soc Nephrol 3 2008 1415 1422
20. L.C. Min, D.B. Reuben, C.H. MacLean, P.G. Shekelle, D.H. Solomon, and T. Higashi Predictors of overall quality of care provided to vulnerable older people J Am Geriatr Soc 53 2005 1705 1711 (Pubitemid 43109933)
21. D.S. Lee, J.V. Tu, D.N. Juurlink, D.A. Alter, D.T. Ko, and P.C. Austin Risk-treatment mismatch in the pharmacotherapy of heart failure JAMA 294 2005 1240 1247
22. R.S. Wright, G.S. Reeder, C.A. Herzog, R.C. Albright, B.A. Williams, and D.L. Dvorak Acute myocardial infarction and renal dysfunction: a high risk combination Ann Intern Med 137 2002 563 570
23. M.G. Shlipak, P.A. Heidenreich, H. Noguchi, G.M. Chertow, W.S. Browner, and M.B. McClellan Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients Ann Intern Med 137 2002 555 562
24. J.N. Beattie, S.S. Soman, K.R. Sandberg, J. Yee, S. Borzak, and M. Garg Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction Am J Kidney Dis 37 2001 1191 1200
25. T.M. Keough-Ryan, B.A. Kiberd, C.S. Dipchand, J.L. Cox, C.L. Rose, and K.J. Thompson Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia Am J Kidney Dis 46 2005 845 855
26. Cardinal H, Bogaty P, Madore F, Boyer L, Joseph L, Brophy JM. Therapeutic management in patients with renal failure who experience an acute coronary syndrome. Clin J Am Soc Nephrol 2010;5:87-94.
27. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
28. N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison beta Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
29. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
30. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth international study of infarct survival) Collaborative Group. Lancet 1995;345:669-85.
31. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, and A.P. Maggioni Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
32. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
33. D. Charytan, and R.E. Kuntz The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease Kidney Int 70 2006 2021 2030
34. G.F. Strippoli, J.C. Craig, and F.P. Schena The number, quality, and coverage of randomized controlled trials in nephrology J Am Soc Nephrol 15 2004 411 419
35. L.K. Newby, M.V. Bhapkar, H.D. White, D.J. Moliterno, N.M. LaPointe, and D.E. Kandzari Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation J Thromb Thrombolysis 16 2003 119 128
36. C. Baigent, M. Landray, C. Leaper, P. Altmann, J. Armitage, and A. Baxter First United Kingdom heart and renal protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease Am J Kidney Dis 45 2005 473 484
37. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch, and S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
38. M.P. Tokmakova, H. Skali, S. Kenchaiah, E. Braunwald, J.L. Rouleau, and M. Packer Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study Circulation 110 2004 3667 3673
39. F. Zannad, M. Kessler, P. Lehert, J.P. Grunfeld, C. Thuilliez, and A. Leizorovicz Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 2006 1318 1324
40. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, and S. Dobson Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 2008 1448 1454 (Pubitemid 351471787)
41. M. Tonelli, C. Isles, G.C. Curhan, A. Tonkin, M.A. Pfeffer, and J. Shepherd Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563
42. G.F. Strippoli, S.D. Navaneethan, D.W. Johnson, V. Perkovic, F. Pellegrini, and A. Nicolucci Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 2008 645 651
43. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, and J. Beutler Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
44. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, and G. Ruf Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
45. C. Herzog, K. Littrel, C. Arko, P. Frederick, and M. Blaney Clinical characteristics of dialysis patients with acute myocardial infarction in the United States Circulation 116 2007 1465 1472
46. D. Reddan, L. Szczech, B. Manjushri, D. Moliterno, R. Califf, and E. Ohman Renal function, concomitant medication use and outcomes following acute coronary syndromes Nephrol Dial Transplant 20 2005 2105 2112